Development of Survivorship Programs

This session entitled the “Development of Survivorship Programs” will present a practical approach to developing a Survivorship Program and embed survivorship strategies in the entire continuum of care for the head and neck cancer patient.  The session will be divided into three main areas:

  1. To understand the importance of and develop pathways for survivorship in the head and neck cancer patient including developing pre-treatment strategies to identify patients at high risk for functional outcome failure.
  2. To develop intervention strategies along the treatment pathways (pre-treatment, during treatment and after treatment) to maximize the best functional outcomes for patients.
  3. To develop post-treatment strategies including understanding the importance of financial toxicity on the patient and the potential for virtual care in the survivorship management of the patient.

 

Target Audience

This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.

 

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Identify an approach to embed survivorship strategies in the entire continuum of care for the head and neck cancer patient.
  • Identify the importance of pathway development for survivorship in the care of the head and neck cancer patient.
  • Develop strategies to recognize patient populations at risk for targeted intervention prior to, during and after treatment.
  • Acquire knowledge for developing in-treatment interventions to improve post-treatment outcomes.
  • Develop post-treatment strategies to attain the best possible functional outcomes.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
02/11/2022
Course expires: 
02/26/2025
Cost:
$0.00
Part of: 
2022 Multidisciplinary Head and Neck Cancers Symposium onDemand
Rating: 
0

Liza Blumenfeld, MA, CCC-SLP, BCS-S, is employed by the University of California, San Diego and has no financial relationships with a commercial interest.

Marci Lee Nilsen, PhD, RN is employed by the University of Pittsburgh and has no financial relationships with a commercial interest.

Jonas de Souza, MD, MBA is employed by HCA Healthcare and has stock options in HCA Healthcare and Humana, Inc. and is on the Board of Directors of Patient Access Network.

All relevant relationships have been mitigated.

 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.